Are you eager to use AI for tailoring immunotherapy for your patients but finding it hard to access the traditional biomarkers you need for predicting response to immune checkpoint inhibitors (ICIs)?

In a new study, funded in part by NCI, researchers tested an AI model, called SCORPIO (“Standard Clinical and labOratory featuRes for Prognostication of Immunotherapy Outcomes”) that leverages a routine blood test, along with basic clinical information.

Using such a tool, you could easily incorporate AI-immunotherapy decision-making into even the busiest clinical practice—anywhere in the world.

Senior author, Dr. Diego Chowell, of the Icahn School of Medicine at Mount Sinai, noted, “SCORPIO helps clinicians prioritize treatment by assessing the risk-benefit ratio of ICIs, especially for patients at risk of immune-related adverse events. SCORPIO also can help you in clinical trial design by selecting patients who are more (or less) likely to benefit from ICIs.”

Co-senior author, Dr. Luc G.T. Morris, of Memorial Sloan Kettering Cancer Center, added, “SCORPIO’s key advantage is its accessibility in all practice settings, including low-resource healthcare environments. Because SCORPIO uses data routinely collected in hospitals and clinics and stored in patient clinical records, it offers an approach that’s noninvasive, cost-effective, and globally accessible.”

For more information on using AI to predict immunotherapy, see the recent article on HistoTME.)